ATOGEPANT IN MIGRAINE PREVENTION: A NARRATIVE REVIEW OF PHARMACOLOGY, CLINICAL EFFICACY AND TOLERABILITY

Jakub Tomczyszyn; Melania Czapla; Aleksandra Obszańska; Julia Tesyna; Karolina Kubala; Kamil Marchlik

doi:10.31435/ijitss.3(51).2026.6293

Authors

Jakub Tomczyszyn Wojewódzki Szpital Specjalistyczny we Wrocławiu: Wroclaw, Lower Silesia, Poland, ul. H. M. Kamieńskiego 73a 51-124 Wrocław, Poland https://orcid.org/0009-0007-1097-0851
Melania Czapla 4th Military Clinical Hospital with Polyclinic SPZOZ in Wroclaw, ul. Rudolfa Weigla 5, 50-981 Wroclaw, Poland https://orcid.org/0009-0002-3401-9757
Aleksandra Obszańska 4th Military Clinical Hospital with Polyclinic SPZOZ in Wroclaw, ul. Rudolfa Weigla 5, 50-981 Wroclaw, Poland https://orcid.org/0009-0000-1823-4655
Julia Tesyna 4th Military Clinical Hospital with Polyclinic SPZOZ in Wroclaw, ul. Rudolfa Weigla 5, 50-981 Wroclaw, Poland https://orcid.org/0009-0004-7995-2369
Karolina Kubala Provincial Specialist Hospital named after J. Gromkowski Ul.Koszarowa 5, 51-149 Wrocław, Poland https://orcid.org/0009-0002-3394-5265
Kamil Marchlik 4th Military Clinical Hospital with Polyclinic SPZOZ in Wroclaw, ul. Rudolfa Weigla 5, 50-981 Wroclaw, Poland https://orcid.org/0009-0000-2530-819X

DOI:

https://doi.org/10.31435/ijitss.3(51).2026.6293

Keywords:

Atogepant, Migraine Prevention, Gepants, Calcitonin Gene-Related Peptide, Chronic Migraine

Abstract

Migraine is a neurological disorder that involves trigeminal and vascular mechanisms. Pain associated with it is not the only issue. Migraine comes with a significant socioeconomic burden – reduced daily functioning, work productivity and general quality of life.

Treatment options for migraine include acute and preventive treatment. Conventional preventive treatments are not always the best option, considering adverse effects, contraindications, quite late benefits and poor long-term adherence.

The pathophysiology of migraine led us to the current main therapeutic target – calcitonin gene-related peptide (CGRP). Gepants, including atogepant, are CGRP signaling antagonists.

This narrative review analyzes atogepant’s pharmacological profile, currently available evidence about clinical efficacy, tolerability and place of atogepant in migraine management.

References

Aditya, S., & Rattan, A. (2023). Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review. Saudi Journal of Medicine & Medical Sciences, 11(1), 11–18. https://doi.org/10.4103/sjmms.sjmms_95_22

Ailani, J., Lipton, R. B., Goadsby, P. J., Guo, H., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2021). Atogepant for the preventive treatment of migraine. New England Journal of Medicine, 385(8), 695–706. https://doi.org/10.1056/NEJMoa2035908

Anukoolwittaya, P., Rattanawong, W., Vongvaivanich, K., Pongpitakmetha, T., Thanprasertsuk, S., Poonpedpun, T., Soontrapa, P., Suwanlaong, K., Kongbunkiat, K., Komonchan, S., Dusitanond, P., Teekaput, C., Sirimaharaj, N., Yuvasilp, N., & Tanprawate, S. (2025). Expert consensus on gepants for acute and preventive treatment of migraine in Thailand. The Journal of Headache and Pain, 26(1), 131. https://doi.org/10.1186/s10194-025-02074-4

Boinpally, R. R., Chandrasekar, P., & Rowe, J. M. (2025). Mass balance and metabolism of 14 C ‐atogepant in healthy male participants: Findings of a phase 1 clinical trial. Clinical and Translational Science, 18(11), e70382. https://doi.org/10.1111/cts.70382

Boinpally, R. R., & Trugman, J. M. (2026). Cerebrospinal fluid and plasma concentrations of atogepant in humans. Clinical and Translational Science, 19(6), e70610. https://doi.org/10.1111/cts.70610

Boinpally, R., Shebley, M., & Trugman, J. M. (2024). Atogepant: Mechanism of action, clinical and translational science. Clinical and Translational Science, 17(1), e13707. https://doi.org/10.1111/cts.13707

Buse, D. C., Fanning, K. M., Reed, M. L., Murray, S., Dumas, P. K., Adams, A. M., & Lipton, R. B. (2019). Life with migraine: Effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache: The Journal of Head and Face Pain, 59(8), 1286–1299. https://doi.org/10.1111/head.13613

European Medicines Agency. (2024). Aquipta: EPAR – product information (EPAR product information). European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/aquipta-epar-product-information_en.pdf

Goadsby, P. J., Friedman, D. I., Holle-Lee, D., Demarquay, G., Ashina, S., Sakai, F., Neel, B., Gandhi, P., Dabruzzo, B., Smith, J. H., Liu, Y., & Trugman, J. M. (2024). Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology, 103(2), e209584. https://doi.org/10.1212/WNL.0000000000209584

Headache Classification Committee of the International Headache Society (IHS). (2018). The international classification of headache disorders, 3rd edition. Cephalalgia: An International Journal of Headache, 38(1), 1–211. https://doi.org/10.1177/0333102417738202

Hou, M., Luo, X., He, S., Yang, X., Zhang, Q., Jin, M., Zhang, P., Li, Y., Bi, X., Li, J., Cheng, C., Xue, Q., Xing, H., & Liu, Y. (2024). Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: A systematic review and meta-analysis. The Journal of Headache and Pain, 25(1), 116. https://doi.org/10.1186/s10194-024-01822-2

Jakubowska, B., & Sowa-Kućma, M. (2025). Gepants: Targeting the CGRP pathway for migraine relief. Frontiers in Pharmacology, 16, 1708226. https://doi.org/10.3389/fphar.2025.1708226

Karsan, N., Gosalia, H., & Goadsby, P. J. (2023). Molecular mechanisms of migraine: Nitric oxide synthase and neuropeptides. International Journal of Molecular Sciences, 24(15), 11993. https://doi.org/10.3390/ijms241511993

Lampl, C., MaassenVanDenBrink, A., Deligianni, C. I., Gil-Gouveia, R., Jassal, T., Sanchez-Del-Rio, M., Reuter, U., Uluduz, D., Versijpt, J., Zeraatkar, D., & Sacco, S. (2023). The comparative effectiveness of migraine preventive drugs: A systematic review and network meta-analysis. The Journal of Headache and Pain, 24(1), 56. https://doi.org/10.1186/s10194-023-01594-1

Lew, C., & Punnapuzha, S. (2026). Migraine medications. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK553159/

Lipton, R. B., Dodick, D. W., Davis, L., Nahas, S. J., & Goadsby, P. J. (2026). Integrating gepants into clinical practice for the acute treatment of migraine. Headache, 66(4), 976–989. https://doi.org/10.1111/head.70047

Martinelli, D., De Icco, R., Al-Khazali, H. M., Ashina, S., Diener, H.-C., Dodd-Glover, F., Goicochea, M. T., Jenkins, B., MaassenVanDenBrink, A., Lee, M. J., Özge, A., Peres, M. F. P., Pozo-Rosich, P., Puledda, F., Sacco, S., Schwedt, T., Terwindt, G. M., & Tassorelli, C. (2026). Advances in migraine prevention. The Lancet. Neurology, 25(3), 279–293. https://doi.org/10.1016/S1474-4422(25)00477-6

Pellesi, L., Do, T. P., & Hougaard, A. (2024). Pharmacological management of migraine: Current strategies and future directions. Expert Opinion on Pharmacotherapy, 25(6), 673–683. https://doi.org/10.1080/14656566.2024.2349791

Pescador Ruschel, M. A., & De Jesus, O. (2026). Migraine headache. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK560787/

Puledda, F., Silva, E. M., Suwanlaong, K., & Goadsby, P. J. (2023). Migraine: From pathophysiology to treatment. Journal of Neurology, 270(7), 3654–3666. https://doi.org/10.1007/s00415-023-11706-1

Russo, A., Silvestro, M., Finkelstein, I., Seabi, D., Ahlden, A., Aamodt, A. H., Caronna, E., Pozo-Rosich, P., Tronvik, E., & Sundal, C. (2025). Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence. Cephalalgia, 45(8), 03331024251370608. https://doi.org/10.1177/03331024251370608

Shaukat, A., Shakeel, L., Riaz, R., Ashraf, S., & Akilimali, A. (2025). The efficacy and safety of atogepant for migraine prophylaxis: A systematic review and meta-analysis of randomized controlled trials. BMC Neurology, 25(1), 326. https://doi.org/10.1186/s12883-025-04350-x

Tassorelli, C., Nagy, K., Pozo-Rosich, P., Lanteri-Minet, M., Sacco, S., Nežádal, T., Guo, H., De Abreu Ferreira, R., Forero, G., & Trugman, J. M. (2024). Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): A randomised, placebo-controlled, phase 3b trial. The Lancet. Neurology, 23(4), 382–392. https://doi.org/10.1016/S1474-4422(24)00025-5

Waliszewska-Prosół, M., Straburzynski, M., Budrewicz, S., Marschollek, K., Nowaczewska, M., Gac, P., & Lipton, R. B. (2025). Consulting, diagnosis and treatment patterns in migraine: Results from the Migraine in Poland cross-sectional survey. 18.